Preliminary report: effects of interleukin-1 on platelet counts.
Recombinant human interleukin-1 beta was given in 5 daily intravenous infusions to ten patients with metastatic malignant disorders as part of an antineoplastic trial. All ten patients experienced transient increases in heart rate, low-grade fevers, and rigors. A neutrophil-dominated 100% rise in leucocyte counts occurred 4-8 h after treatment. Leucocyte counts returned to baseline levels within 24 h of interleukin-1 beta infusion. A 50% rise in platelets occurred in response to interleukin-1 beta; the increase in platelet counts was first noted 6 days after treatment began and was sustained for 24 days after treatment. Interleukin-1 beta may therefore be beneficial in the treatment of conditions of thrombocytopenia associated with haematological disorders and chemotherapy for malignant disorders.
Tewari
A
A
Department of Surgery, Stanford University, California 94305-5101.
Buhles
W C
WC
Starnes
H F
HF
D000328:Adult; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D007375:Interleukin-1 / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D007377:Interleukin-3 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D009504:Neutrophils; D010976:Platelet Count / Q000187:drug effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy; D013997:Time Factors
D007375:Interleukin-1; D007377:Interleukin-3; D015850:Interleukin-6; D011994:Recombinant Proteins